The global paraganglioma market size is estimated to be valued at USD 373.2 Million in 2025. It can reach a valuation of USD 425.8 Million by 2032, by exhibiting a CAGR of 1.9% throughout the forecast period (2025-2032).  

The cases of rare tumors and advances in diagnostic technologies can drive the market growth. Increasing investments in the research of rare diseases can fuel the development of orphan drugs and entice private players to take an interest in the disease.

However, the high costs of treatment of paraganglioma can impede the market growth.

Key Market Insights

The paraganglioma market is expected to be shaped by next-generation sequencing (NGS) and the growing use of AI in diagnostic radiology.

• By treatment, the radiation therapy segment is expected to capture a 34% share of the market in 2025. This can be attributed to its use in tumor control and providing relief in inoperable cases. Precise targeting made possible by modern approaches such as stereotactic body radiation therapy (SBRT) and intensity-modulated radiation therapy (IMRT) can drive the segment’s growth over the forecast period.
• By end user, the specialty clinics segment is expected to capture 23% share of the market in 2025. The availability of targeted therapies and the focus on specialized care at these clinics can drive the segment growth significantly.
• By region, Europe is anticipated to capture a significant share of the paraganglioma market in 2025. This is on the account of ongoing research on paraganglioma supported by cross-border collaborations and centralized rare disease networks. Incentives for orphan drugs and a focus on patient safety can bode well for the market in the region.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/paraganglioma-market

Paraganglioma Market Report Coverage

Market Dynamics

The awareness of neuroendocrine tumors like paraganglioma and the demand for innovative therapies is expected to drive the market growth. The advances in NGS for the diagnosis of hereditary paragangliomas can improve survival rates and proactive monitoring of the disease. Advanced imaging techniques like F-DOPA PET scans for diagnosing the precise localization of tumors can facilitate the market growth.

Targeted research on paraganglioma for the identification of specific genetic mutations and research into SDHx-mutated tumors can bode well for the market. The targeting of tumor-specific pathways for reducing damage to healthy tissue and the use of binding agents to eliminate tumors can bolster the paraganglioma market growth.

Market Opportunity: Development of Novel Orphan Drugs

The discontinuation of Iobenguane I 131 due to adverse side effects and the lack of effects of tyrosine kinase inhibitors (TKIs) can provide new opportunities for pharmaceutical manufacturers. The approval of belzutifan for patients with advanced paraganglioma can open the doors for novel drugs. This requires large-scale clinical trials and the elimination of side effects found in previous formulations.

Market Challenge: High Toxicity Levels of Approved Drugs

The limited number of drugs being approved for the treatment of paraganglioma can pose hurdles for the market growth. Adverse effects of musculoskeletal pain and nausea, as well as their continuation till disease progression due to a lack of alternative therapies, can negatively impact the market growth. Furthermore, the paucity of drugs for the treatment of pediatric patients from ages 3 to 11 with paraganglioma is a major challenge for the market.

Analyst’s View

• The advances in NGS and the development of targeted therapies can drive the paraganglioma market.
• The specialty clinics segment is anticipated to perform exceptionally owing to the presence of various specialists in nuclear medicine, surgical oncology, and endocrinology.
• Key players are increasing their investments in research on endocrine tumors and clinical trials on the treatment of paraganglioma.

Recent Developments

Belzutifan, a selective HIF-2α inhibitor, developed by Merck, has been granted approval by the U.S. FDA for the treatment of paraganglioma on March 14, 2025.

Competitor Insights

• Bayer AG
• Merck & Co., Inc.
• Novartis AG
• Amgen Inc.
• AstraZeneca PLC
• Pfizer Inc.
• Eli Lilly and Company
• Oncomed manufacturing a.s.
• Immunomedics

Market Segmentation

• By Treatment

• Surgery
• Open Surgery
• Minimally Invasive Surgery
• Radiation Therapy
• External Beam Radiation
• Stereotactic Radiosurgery
• Chemotherapy
• Alkylating Agents
• Antimetabolites
• Targeted Therapy
• Tyrosine Kinase Inhibitors
• Angiogenesis Inhibitors

• By End User

• Hospitals
• Public Hospitals
• Private Hospitals
• Specialty Clinics
• Oncology Clinics
• Endocrinology Clinics
• Ambulatory Surgical Centers
• Independent ASCs
• Hospital-Affiliated ASCs

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa